A carregar...
Quantification of cerivastatin toxicity supports organismal performance assays as an effective tool during pharmaceutical safety assessment
A major problem in pharmaceutical development is that adverse effects remain undetected during preclinical and clinical trials, but are later revealed after market release when prescribed to many patients. We have developed a fitness assay known as the organismal performance assay (OPA), which evalu...
Na minha lista:
| Publicado no: | Evol Appl |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4869410/ https://ncbi.nlm.nih.gov/pubmed/27247619 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/eva.12365 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|